IRWD

IRWD

Ironwood Pharmaceuticals Inc. Class A Common Stock

$0.708+0.000 (0.000%)

即時價格

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$0.708

最高

$0.708

最低

$0.708

交易量

0.85M

公司基本面

交易統計

相關新聞

BusinessWire

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

– On track to achieve FY 2025 financial guidance; raised adjusted EBITDA guidance to greater than $105 million for 2025 – – LINZESS® (linaclotide) EUTRx prescription demand growth of 8% year-over-year; in line

查看更多
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
BusinessWire

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

– Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in

查看更多
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
BusinessWire

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

– Additional presentations will highlight results from Phase III study evaluating linaclotide in pediatric patients aged 7-17 years with irritable bowel syndrome with constipation (IBS-C); first completed Phase III

查看更多
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support